MOESM2 of Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
Michael Gowen
Keith Giles
Danny Simpson
Jeremy Tchack
Hua Zhou
Una Moran
Zarmeena Dawood
Anna Pavlick
Shaohui Hu
Melissa Wilson
Hua Zhong
Michelle Krogsgaard
Tomas Kirchhoff
Iman Osman
10.6084/m9.figshare.6072518.v1
https://springernature.figshare.com/articles/journal_contribution/MOESM2_of_Baseline_antibody_profiles_predict_toxicity_in_melanoma_patients_treated_with_immune_checkpoint_inhibitors/6072518
Additional file 2: Table S2. Patient characteristics for reproducibility cohort (n = 10). Summary of clinical features from independent group of 10 melanoma patients treated with anti-CTLA-4 (n = 3), anti-PD-1 (n = 3), or combined anti-CTLA-4/anti-PD-1 (n = 4), and from whom serum samples were used to assess assay reproducibility. LDH, lactate dehydrogenase; POD, progression of disease; SD, stable disease; PR, partial response; CR, complete response; UNC, unclassified.
2018-04-02 05:00:00
Melanoma
Immunotherapy
Antibodies
Toxicity
Biomarker